Journals
Publish with us
Publishing partnerships
About us
Blog
Journal of Immunology Research
Journal overview
For authors
For reviewers
For editors
Table of Contents
Special Issues
Journal of Immunology Research
/
2014
/
Article
/
Tab 4
/
Clinical Study
Serum SALL4 Is a Novel Prognosis Biomarker with Tumor Recurrence and Poor Survival of Patients in Hepatocellular Carcinoma
Table 4
The serum levels of SALL4 of 40 HCCs before and after treatment (pg/mL).
Variables
Median
IQR
Before treatment
152.54
103.12–277.26
<0.0001
1 week after treatment
220.42
118.64–371.06
1 month after treatment
80.12
48.07–131.72